Nevertheless, further clinical investigations are necessary to evaluate the correlation between SMAD4 status and the survival advantages of radiotherapy in pancreatic cancer patients, which could potentially help guide the administration of targeted therapies in the adjuvant setting based on SMAD4 status. This evidence concerns the gene SMAD4 and familial pancreatic carcinoma.